Target Corporation logo

Target Corporation (TGT)

Market Closed
5 Jun, 20:00
NYSE NYSE
$
122. 57
-1.28
-1.0335%
$
55.67B Market Cap
17.63 P/E Ratio
23.53% Div Yield
4.38M Volume
5.54 Eps
$ 123.85
Previous Close
Add Transaction
Day Range
121.79 124.08
Year Range
83.44 133.1
Want to track TGT and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Target Q3 Earnings Preview: From $500M Loss To 40% EPS Growth

Target Q3 Earnings Preview: From $500M Loss To 40% EPS Growth

Analysts are optimistic about Target, expecting $26B in revenue and a 9.5% YoY EPS growth, despite mixed top-line revisions. Target faced challenges with shrinkage, but recent efforts have shown improvement, contributing to a $500M efficiency gain. FY 2023 results were strong with a 50% YoY EPS increase and higher operating margins, though comparable sales were declining.

Seekingalpha | 1 year ago
How is Target Stock Performing Before Earnings?

How is Target Stock Performing Before Earnings?

Target Corp (NYSE:TGT) is set to step into the earnings confessional, where it will announce third-quarter results before the market open on Wednesday, Nov. 20.

Schaeffersresearch | 1 year ago
Target (TGT) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

Target (TGT) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

Target (TGT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks | 1 year ago
Target (TGT) Advances While Market Declines: Some Information for Investors

Target (TGT) Advances While Market Declines: Some Information for Investors

In the latest trading session, Target (TGT) closed at $155.65, marking a +1.55% move from the previous day.

Zacks | 1 year ago
1606 Corp. Target for Strategic Investment Adnexus Biotechnologies Merges With Sanctum Therapeutics to Obtain Breakthrough HIV and SARS-CoV-2 Treatments

1606 Corp. Target for Strategic Investment Adnexus Biotechnologies Merges With Sanctum Therapeutics to Obtain Breakthrough HIV and SARS-CoV-2 Treatments

SEATTLE, WA / ACCESSWIRE / November 12, 2024 / 1606 Corp. (OTC PINK:CBDW) (the "Company" or "1606"), a leader in AI technology, acquisition target Adnexus Biotechnologies Inc. is delighted to reveal the completion of a merger agreement to acquire Sanctum Therapeutics core technology assets for treating HIV and SARS-CoV-2. This merger will combine the two biotechnology companies' significant resources and expertise.

Accesswire | 1 year ago
Target to undershoot sales guidances, predict Citi analysts

Target to undershoot sales guidances, predict Citi analysts

Target Corp (NYSE:TGT) is expected to post lower-than-expected sales in its upcoming third-quarter earnings report, according to Citi analysts. Citi projects comparable sales growth at 1%, compared to the market's 1.6% expectation.

Proactiveinvestors | 1 year ago
BlueBird: Adding To My Position With A 100% Upside Target

BlueBird: Adding To My Position With A 100% Upside Target

BlueBird (BLBD) is a Strong Buy with a $91 target, driven by its monopoly on alternative-fueled buses and significant revenue growth potential. Despite potential policy changes, BlueBird's propane and gasoline buses provide a competitive edge, meeting new EPA standards and offering lower total ownership costs. BlueBird's financial health is robust, with record profits, zero debt, and a government grant to boost production capacity by 40% in two years.

Seekingalpha | 1 year ago
HIV Drugmaker Gilead Reports Strongest Quarterly Performance Of 2024, Analysts Boost Price Target On Raised Outlook

HIV Drugmaker Gilead Reports Strongest Quarterly Performance Of 2024, Analysts Boost Price Target On Raised Outlook

Gilead Sciences Inc GILD stock is trading higher on Thursday after the company reported better-than-expected third-quarter financial results and raised its fiscal year 2024 guidance.

Benzinga | 1 year ago
Should Value Investors Buy Target (TGT) Stock?

Should Value Investors Buy Target (TGT) Stock?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Zacks | 1 year ago
Target Corporation (TGT) Is a Trending Stock: Facts to Know Before Betting on It

Target Corporation (TGT) Is a Trending Stock: Facts to Know Before Betting on It

Zacks.com users have recently been watching Target (TGT) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Zacks | 1 year ago
Church & Dwight: Growth Target Is Achievable, But The Stock Is Still Expensive

Church & Dwight: Growth Target Is Achievable, But The Stock Is Still Expensive

I reiterate a hold rating on Church & Dwight Co. due to its expensive valuation compared to peers despite strong 3Q24 performance. CHD's net sales grew 3.8% y/y, beating estimates, with a 4.3% organic sales growth driven by volume and price/mix. Management's increased marketing spend and improved consumer spending environment should support CHD's growth, but valuation concerns remain.

Seekingalpha | 1 year ago
Target Plans Holiday-Themed Upgrades In Store and Online

Target Plans Holiday-Themed Upgrades In Store and Online

Target is getting a holiday makeover as retailers prepare for a potentially tepid shopping season.

Pymnts | 1 year ago
Loading...
Load More